Alcidion Group

Alcidion Group EPS Growth

The EPS Growth of Alcidion Group (ALC.AX) as of Nov 11, 2026 is 38.14 %. In the previous year, EPS Growth was 119.65 % — a change of -68.13% (lower).

EPS Growth

38.14 %

YoY

-68.13%

Last updated:

EPS Growth of Alcidion Group is 2026 38.14 % . EPS Growth of Alcidion Group was 2025 119.65 % . It decreases by -68.13% lower compared to the previous year.

The Alcidion Group EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2019
96.35 AUD
Jan 1, 2020
-3,116.54 AUD
Jan 1, 2021
31.39 AUD
Jan 1, 2022
-66.47 AUD
Jan 1, 2023
19.44 AUD
Jan 1, 2024
-123.63 AUD
Jan 1, 2025
119.65 AUD
Jan 1, 2026
38.14 AUD
The Alcidion Group EPS Growth history
YEAREPS GrowthYoY
38.14 %-68.13%
119.65 %-196.78%
-123.63 %-736.10%
19.44 %-129.24%
-66.47 %-311.73%
31.39 %-101.01%
-3,116.54 %-3,334.51%
96.35 %+311.37%
23.42 %+23.21%
19.01 %-106.09%
-312.24 %-5,784.59%
5.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alcidion Group Stock analysis

What does Alcidion Group do? Alcidion Group Ltd. generates revenue through the development and licensing of its healthcare software products, including Miya Precision, Miya Observations, Flow, Task Management, and PAS, marketed under the Miya brand. The company also resells selected healthcare software from strategic partners and provides implementation, support, maintenance, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its flagship product Miya Precision, a FHIR-event platform-based solution, supports clinical and operational applications, while Smartpage offers hospital communication and task management via smartphone and web. The firm serves over 400 hospitals across its key markets. Miya Precision and its associated modules form the core of Alcidion's product portfolio, targeting hospitals seeking integrated clinical solutions. Smartpage, Patientrack, and Silverlink PCS complement these offerings, catering to diverse healthcare communication and operational needs. The company’s revenue streams are driven by direct sales of software licenses, ongoing service contracts, and partner resales, with a focus on the Australian, New Zealand, and UK healthcare sectors. Alcidion’s business model emphasizes software licensing and service delivery, with Miya Precision as the primary revenue generator. The company’s strategic partnerships enable it to resell third-party software, expanding its product range without additional development costs. Healthcare institutions in Australia, New Zealand, and the United Kingdom are the primary buyers, leveraging Alcidion’s solutions for improved clinical workflows and operational efficiency. Alcidion Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alcidion Group stock

EPS Growth of Alcidion Group is 38.14 % in 2026.

On Eulerpool you can find the complete historical development of EPS Growth Alcidion Group since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Alcidion Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Alcidion Group

All Key Metrics — Alcidion Group